AR and prostate carcinoma: The history of androgen receptor (AR) targeting in prostate cancer (PCa) began with the landmark discovery by Charles Huggins and Clarence V. Hodges in 1941, showing that androgen deprivation, through orchiectomy or synthetic estrogens like stilbestrol, reduced levels of acid phosphatase, an early PCa biomarker [2].